Emily A. Ricke

Emily A. Ricke

Auto-generated profile, based on publicly available information

Emily A. Ricke

Department of Urology, George M. O'Brien Center of Research Excellence University of Wisconsin–Madison Madison WI USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JVJordan E. Vellky
Jordan E. Vellky
SMSean McSweeney
Sean McSweeney
EREmily A. Ricke
Emily A. Ricke
WRWilliam Ricke
William Ricke
Significance: Little is known regarding the mechanisms involved in loss of androgen receptor (AR) function in the development of castration resistance. Recently, the clinical use of new potent AR therapies has led to the emergence of a new lethal subtype of castration-resistant prostate cancer (CRPC) lacking AR protein and signaling, termed ARL/negative CRPC. We discovered that DDX3 (DEAD-box helicase 3 X-linked) is a key repressor of AR protein translation—a mechanism that leads to development of castration resistance. Inhibition of DDX3 in ARL/negative CRPC promotes the expression of AR protein/signaling and hence sensitivity to hormone therapy. These data provide a molecular mechanism for hormone action and describe a synthetic lethality approach to the clinical treatment of therapy-resistant diseases such as CRPC.

1 May 2020 in The Prostate
Verified
Journal Article
Closed access
PDF file
PPPetra Popovics
Petra Popovics
WAWisam N. Awadallah
Wisam N. Awadallah
SKSarah E. Kohrt
Sarah E. Kohrt
TCThomas C. Case
Thomas C. Case
NMNicole L. Miller
Nicole L. Miller
MGMagdalena M. Grabowska
Magdalena M. Grabowska

1 January 1999 in Journal of Animal Science
Verified
Journal Article
Closed access
PDF file
ERE A Ricke
E A Ricke
DSD. J. Smith
D. J. Smith
VFV. J. Feil
V. J. Feil
GLG. L. Larsen
G. L. Larsen
JCJ. S. Caton
J. S. Caton
The objectives of this study were to determine the effects of ractopamine HCl (RAC) stereoisomers (RR, RS, SR, and SS) on performance, carcass composition, and nitrogen retention in growing female rats. Forty-eight rats (eight rats/treatment) were treated with 0 or 320 µ/d of RAC or with 80 µg/d of the RR, RS, SR, or SS stereoisomers of ractopamine. Rats had free access to feed and water before and during the experiment. Ractopamine and stereoisomers were delivered via i.p. implanted osmotic pumps for 14 d, and rats were then slaughtered. Control rats were fitted with osmotic pumps containing saline. Ractopamine increased (P < .05) feed intake (d 1 to 6); body weight; carcass CP; and intake, apparent absorption, retention, and retained:intake ratio of CP on d 1 to 6 of the study. Ractopamine decreased (P < .05) carcass lipid and visceral lipid. Rats dosed with the RR stereoisomer responded similarly to rats dosed with RAC, except for carcass lipid. Carcass lipid was decreased (P < .01) by RAC relative to controls, but it was not different from controls in rats treated with the RR isomer. Compared with controls, BW, carcass CP, and CP retention were increased by the RR stereoisomer, and visceral lipid was decreased. The RS isomer also decreased visceral lipid (P < .10), but variables measured in rats dosed with the RS, SR, and SS isomers generally did not differ from controls. Results of this study indicate that the RR isomer of RAC is responsible for a majority of the leanness-enhancing effects of RAC in rats.

8 October 2020 in The American Journal of Pathology
Verified
Journal Article
Closed access
JVJordan E. Vellky
Jordan E. Vellky
EREmily A. Ricke
Emily A. Ricke
WHWei Huang
Wei Huang
WRWilliam Ricke
William Ricke

29 November 2025 in The Journal of Pathology
Verified
Journal Article
Open access
TLTeresa T Liu
Teresa T Liu
LPLaura E Pascal
Laura E Pascal
EREmily A Ricke
Emily A Ricke
ABAna Lucila Bautista‐Ruiz
Ana Lucila Bautista‐Ruiz
JTJustin Townsend
Justin Townsend
WRWilliam Ricke
William Ricke
Lower urinary tract symptoms (LUTS), associated with benign prostatic hyperplasia (BPH), are an aging‐related disease, with more than 210 million cases worldwide. Estrogen exposure and estrogen regulation have been implicated in a variety of disease processes, with estrogen receptor (ER)‐α pathways associated with disease progression and ERβ pathways considered to be disease‐protective through enhanced apoptosis and reduced cellular proliferation. Preclinical models of LUTS/BPH have shown that ERα activation contributes to disease initiation and progression. Self‐identified African American (AA) men have a high incidence of LUTS/BPH, with increased incidence of non‐surgical treatment failure, larger prostates at time of surgery, and surgery occurring at a younger age compared with self‐identified European American (EA) men. While circulating estrogen levels are higher in AA individuals, regulation of ERs, particularly ERβ, in normal and LUTS/BPH human prostate has not been well characterized. In this study, we examined differences in ER expression between peripheral zone (PZ) and transition zone (TZ) prostate tissues using multiplex, multispectral imaging. Additionally, we assessed changes in ERs and steroid metabolism genes involved in ERβ signaling between normal and LUTS/BPH prostate samples. Our study revealed underlying differences in steroid metabolism gene expression between normal AA and EA prostates, which were further altered with LUTS/BPH. Importantly, the contribution of ERα to LUTS/BPH was more pronounced in EA prostate samples, whereas AA prostate samples exhibited an overall increase in the expression of both ER and estrogen metabolism‐related genes. Although estrogens have also been implicated in collagen deposition in the prostate of LUTS/BPH patients, we did not observe significant differences in collagen deposition between AA and EA samples. These results suggest that racial differences in steroid hormone signaling pathways within the benign prostate represent a promising area for the development of precision‐based therapies to reduce LUTS in aging men. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.